Chrysos (C79) Q4 2024 earnings summary

Executive summary

• FY24 revenue grew 58% year-on-year and 5% quarter-on-quarter to $45.4 million, with Q4 revenue at $13.5 million and strong international expansion in EMEA (up 157%) and Americas (up 232%).

• 1.2 million samples processed in Q4 FY24, up 27% year-on-year and 17% quarter-on-quarter, marking the 22nd consecutive quarter of record PhotonAssay volumes.

• 29 PhotonAssay units deployed globally as of June 30, 2024, with two new units added in Q4 and 52 units contractually committed, including new contracts signed post-quarter.

• Strong cash position with $61 million in the bank and $95 million undrawn debt, totaling $156 million available for growth.

• Expanded customer base with new PhotonAssay lease agreements in Africa and continued global rollout, including Barrick Gold and SGS installations.

Financial highlights

• FY24 unaudited revenue reached $45.4 million, with international markets contributing over half of total revenues for three consecutive quarters.

• Gross margins remained strong at 70–80%.

• Cash collections improved and are now more closely aligned with revenues, though some regions experience slower payment cycles.

• Net operating cash inflow for Q4 was $4.4 million.

• Record sample volumes up 27% year-on-year, supporting top-line growth.

Outlook and guidance

• FY25 revenue guidance is $60–70 million, implying ~45% growth at the midpoint, with EBITDA guidance of $9–19 million and margin improvement expected from cost control and clustering strategy.

• Guidance assumes stable market conditions and revenue per unit similar to FY24, with upside potential if macro conditions improve or deployments accelerate.

• 14 units are ready for shipment and installation to support FY25 deployment schedule.